pharmaceutical innovation
Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat
ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health
Altanine Strengthens Scientific Advisory Board with Appointment of Dr. Bruce D. Forrest
Altanine; Scientific Advisory Board; Bruce D. Forrest; drug delivery; clinical strategy; regulatory expertise; biopharmaceutical development; vaccine development; pharmaceutical innovation
Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook
Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing
Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation
Eisai Adopts Elix Discovery Platform to Accelerate AI-Driven Drug Development
Eisai; Elix Discovery; AI drug discovery; federated learning; pharmaceutical innovation; joint research; Japan; DAIIA initiative
NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery
NVIDIA; Novo Nordisk; AI models; drug discovery; Gefion AI Supercomputer; BioNeMo; Omniverse; pharmaceutical innovation
PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics
PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation
Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data
Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation
GSK’s Strategic Approach to Deal-Making and Expansion Beyond Obesity with GLP-1s
GSK, GLP-1s, Obesity, Deal-making, Strategic expansion, Pharmaceutical innovation, R&D strategy
Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery
Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation